Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer

Tsai, Henry K., Chen, Ming‐Hui, McLeod, David G., Carroll, Peter R., Richie, Jerome P., D'Amico, Anthony V.·2006·Cancer

Abstract

BACKGROUND.: The presence of multiple determinants of aggressive cancer biology may impact prostate cancer‐specific mortality (PCSM) rates compared with fewer factors. The authors estimated PCSM after radiation therapy with short‐course androgen suppression therapy (RT+AST) or radical prostatectomy (RP) in men with clinically localized, intermediate‐risk to high‐risk prostate cancer. METHODS.: The study cohort included 3240 men treated from 1981 to 2002 with RT with 6 months of AST (n = 550) or RP (n = 2690) for localized prostate cancer with at least 1 risk factor (prostate‐specific antigen [PSA] >10 ng/mL, biopsy Gleason score 7–10, or clinical tumor category T2b or T2c). Competing risks regression analyses were used to determine whether the number of risk factors present was associated with time to PCSM. RESULTS.: Men with all 3 risk factors had significantly shorter time to PCSM after RT+AST (adjusted hazards ratio [HR] of 9.3; 95% confidence interval [95% CI], 1.9–44.5 [PGray = .005]) or RP (adjusted HR of 6.3; 95% CI, 3.2–12.2 [PGray < .001]) when compared with men with any 1 or 2 risk factors. The 7‐year estimates of PCSM for men having 1, 2, or 3 risk factors were 0.83% (95% CI, 0.27–1.4%), 2.6% (95% CI, 1.0–4.2%), and 12.6% (95% CI, 7.1–18.1%), respectively. CONCLUSIONS.: Men with multiple determinants of intermediate‐risk to high‐risk prostate cancer have significantly increased estimates of PCSM despite aggressive therapy compared with men with only 1 or 2 determinants. These men are appropriate candidates for enrollment onto randomized controlled trials evaluating the benefit of adding systemic therapies such as docetaxel to RT+AST or RP. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22279

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 166

Metadata

Authors
Tsai, H. K., Chen, M., McLeod, D. G., Carroll, P. R., Richie, J. P., & D'Amico, A. V.
Venue
Cancer
Publisher
Wiley
Published
2006-10-12
Volume
107
Issue
11
Pages
2597-2603
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2002681681
Cited by
166
References
3
FWCI
18.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer. https://app.cochat.ai/papers/10.1002/cncr.22279
The paper
Tsai, H. K., Chen, M., McLeod, D. G., Carroll, P. R., Richie, J. P., & D'Amico, A. V. (2006). Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer. Cancer. https://doi.org/10.1002/cncr.22279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.